Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €14.42 EUR
Change Today +0.024 / 0.17%
Volume 0.0
As of 7:10 AM 03/27/15 All times are local (Market data is delayed by at least 15 minutes).

luminex corp (LMX) Snapshot

Open
€14.36
Previous Close
€14.39
Day High
€14.61
Day Low
€14.36
52 Week High
10/10/14 - €16.98
52 Week Low
04/29/14 - €11.35
Market Cap
618.7M
Average Volume 10 Days
20.0
EPS TTM
--
Shares Outstanding
42.9M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for LUMINEX CORP (LMX)

Related News

No related news articles were found.

luminex corp (LMX) Related Businessweek News

No Related Businessweek News Found

luminex corp (LMX) Details

Luminex Corporation develops, manufactures, and sells proprietary biological testing technologies and products for the diagnostics and life sciences industries worldwide. It offers xMAP technology, an open architecture, multiplexing technology that allows simultaneous analysis of approximately 500 bioassays from a drop of fluid by reading biological tests on the surface of microscopic polystyrene beads called microspheres; and MultiCode technology used for real-time polymerase chain reaction (PCR) and multiplexed PCR assays. The company’s products include Luminex LX 100/200 that integrates fluidics, optics, and digital signal processing; FLEXMAP 3D system for use as a general laboratory instrument; and MAGPIX system, a multiplexing analyzer for qualitative and quantitative analysis of proteins and nucleic acids. It also offers MicroPlex, MagPlex, xTAG, SeroMAP, and calibration and control microspheres; xPONENT, a software suite to simplify laboratory workflow and enhance productivity; respiratory viral family of products, including respiratory viral panel to identify the causative agent for respiratory infections; and gastrointestinal pathogen panel family of products, such as in vitro diagnostic (IVD) assays to identify the pathogens causing infectious gastroenteritis. In addition, the company offers MultiCode assays and products comprising HSV1/2 kits, analyte specific reagents, and other products to detect infectious agents in clinical samples; cystic fibrosis family of products comprising IVD kits for cystic fibrosis genotyping; personalized medicine family of products consisting of assays to determine the drug metabolism status; and specialty product family and instrumentation products, as well as operates an original equipment manufacturer of custom reagents and instrumentation. It serves pharmaceutical companies, clinical laboratories, and research and medical institutions. Luminex Corporation was founded in 1995 and is headquartered in Austin, Texas.

745 Employees
Last Reported Date: 02/25/15
Founded in 1995

luminex corp (LMX) Top Compensated Officers

Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $360.5K
Chief Marketing & Sales Officer and Senior Vi...
Total Annual Compensation: $319.2K
Senior Vice President of Research & Developme...
Total Annual Compensation: $345.6K
Compensation as of Fiscal Year 2013.

luminex corp (LMX) Key Developments

Assurex Health Selects Luminex Corporation's xTag Technology

Luminex Corporation announced that its xTAG Technology has been selected for use in enhancing the processing speed and capacity of Assurex Health's patented GeneSight tests. Healthcare providers use GeneSight to help patients affected by neuropsychiatric conditions including depression, posttraumatic stress disorder (PTSD), anxiety, bipolar disorder, schizophrenia, ADHD, and acute and chronic pain. This agreement incorporates the company's open-architecture xTAG Technology into the GeneSight testing process and enables large numbers of tests to be conducted and analyzed quickly, cost-effectively, and accurately.

Luminex Corporation Announces Amendments to the Articles of Incorporation

On March 4, 2015, the Board of Directors of Luminex Corporation adopted an amendment and restatement of the Company's amended and restated by-Laws to adopt a majority voting standard and director resignation process for uncontested director elections. The amendment and restatement affects Article III, Section 3.3 of the Company's Amended and Restated By-Laws. The Amended By-Laws became effective immediately upon their adoption by the Board. The Company's Amended and Restated Bylaws previously provided for a plurality voting standard in all director elections. The Amended By-Laws provide that in order to be elected in an uncontested election, a director nominee must receive a majority of the votes cast with respect to that nominee's election such that the number of votes cast for a nominee's election exceeds the number of votes withheld from that nominee. Abstentions and broker nonvotes are not counted as votes cast with respect to a nominee and will have no effect on the outcome of the election of directors. If an incumbent director nominee fails to receive for" votes representing a majority of the votes cast, the director is required to promptly tender his or her resignation to the Board, subject to acceptance by the Board. The Board's Nominating and Corporate Governance Committee would then be charged with making a recommendation to the Board as to the action to be taken with respect to the tendered resignation.

Luminex Corporation Announces Executive Appointments

Luminex Corporation has appointed Richard W. Rew, II, as Senior Vice President, General Counsel and Corporate Secretary, effective March 4, 2015, and Mr. Randall Myers, as Senior Vice President, Global Manufacturing and Quality, effective March 16, 2015. Prior to joining the Company, Mr. Rew served as Senior Vice President, General Counsel and Secretary at ArthroCare Corporation from December 2008 until they were acquired by Smith & Nephew in 2014. Mr. Rew joined ArthroCare in 2006 as its Vice President, Legal Affairs. Prior to joining the Company, Mr. Myers accepted an early retirement from Applied Materials in 2012 and has been consulting in supply chain and manufacturing operations since that time. Prior to his retirement, Mr. Myers held various positions at Applied Materials in manufacturing and operations from 1995-2012.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
LMX:GR €14.42 EUR +0.024

LMX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Computer Programs & Systems Inc $52.69 USD +0.73
HealthStream Inc $24.67 USD +0.04
Merge Healthcare Inc $4.45 USD +0.11
Meridian Bioscience Inc $19.13 USD -0.08
Quidel Corp $26.52 USD -0.38
View Industry Companies
 

Industry Analysis

LMX

Industry Average

Valuation LMX Industry Range
Price/Earnings 17.2x
Price/Sales 2.9x
Price/Book 2.1x
Price/Cash Flow 15.9x
TEV/Sales 2.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact LUMINEX CORP, please visit www.luminexcorp.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.